Anika Therapeutics Inc
NASDAQ:ANIK

Watchlist Manager
Anika Therapeutics Inc Logo
Anika Therapeutics Inc
NASDAQ:ANIK
Watchlist
Price: 16.28 USD -0.19%
Market Cap: 238.5m USD
Have any thoughts about
Anika Therapeutics Inc?
Write Note

Anika Therapeutics Inc
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Anika Therapeutics Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Anika Therapeutics Inc
NASDAQ:ANIK
Total Liabilities
$51.5m
CAGR 3-Years
-6%
CAGR 5-Years
6%
CAGR 10-Years
13%
Abbvie Inc
NYSE:ABBV
Total Liabilities
$137.4B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities
$36.1B
CAGR 3-Years
-7%
CAGR 5-Years
-1%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Total Liabilities
$83.4B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities
$6.6B
CAGR 3-Years
29%
CAGR 5-Years
24%
CAGR 10-Years
18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities
$8.1B
CAGR 3-Years
8%
CAGR 5-Years
19%
CAGR 10-Years
21%
No Stocks Found

Anika Therapeutics Inc
Glance View

Market Cap
239.2m USD
Industry
Biotechnology

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. The company is headquartered in Bedford, Massachusetts and currently employs 297 full-time employees. The firm is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product include OA Pain Management product consists of Monovisc and Orthovisc, which is single and multi-injection, HA-based viscosupplement product, Cingal, and Hyvisc; Joint Preservation and Restoration product consists of bone preserving joint technologies, soft tissue repair and regenerative solutions, and Non-Orthopedic product consists of Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries. Hyalomatrix is used for the treatment of wounds, such as burns, ulcers, ears, nose and throat disorders, and ophthalmic products.

ANIK Intrinsic Value
12.08 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Anika Therapeutics Inc's Total Liabilities?
Total Liabilities
51.5m USD

Based on the financial report for Sep 30, 2024, Anika Therapeutics Inc's Total Liabilities amounts to 51.5m USD.

What is Anika Therapeutics Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
13%

Over the last year, the Total Liabilities growth was -11%. The average annual Total Liabilities growth rates for Anika Therapeutics Inc have been -6% over the past three years , 6% over the past five years , and 13% over the past ten years .

Back to Top